Edoxaban and/or colchicine in outpatients with COVID-19: rationale and design of the CONVINCE trial

aCardiocentro Ticino Institute, Ente Ospedaliero Cantonale (EOC)

bDepartment of Biomedical Sciences, University of Italian Switzerland, Lugano, Switzerland

cIRCCS S. Maria Nascente - Fondazione Don Carlo Gnocchi ONLUS, Milan, Italy

dthe Faculty of Medicine and Life Sciences, Hasselt University, Hasselt, Belgium

eEmergency Department, ASST Great Metropolitan Hospital Niguarda, Milan

fEmergency Unit, ASST Rhodense, Garbagnate Milanese, Italy

gUnit of General Medicine and Advanced Care, IRCCS San Raffaele Hospital, Milan

hDepartment of Anesthesiology, Clinica Ars Medica, Genolier Swiss Medical Network, Gravesano

iStudi Medici Riuniti & Partners, Lugano

jUniversity of Bern, Bern, Switzerland

Correspondence to Prof. Marco Valgimigli, MD, PhD, Cardiocentro Ticino Institute, Ente Ospedaliero Cantonale, Via Tesserete, 48, CH-6900 Lugano, Switzerland Tel: +41 91 811 53 47; fax: +41 91 811 30 34; e-mail: [email protected]

Received 6 June, 2023

Revised 19 July, 2023

Accepted 12 August, 2023

Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Website (www.jcardiovascularmedicine.com).

留言 (0)

沒有登入
gif